# Vancomycin Efficacy in Response to Dysbiosis in Atypical Colitis

> **NCT07646223** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Tampere University Hospital** · enrollment: 140 (estimated)

## Conditions studied

- Ulcerative Colitis (UC)
- Primary Sclerosing Cholangitis (PSC)
- Pediatric Inflammatory Bowel Diseases

## Interventions

- **DRUG:** Oral Vancomycin

## Key facts

- **NCT ID:** NCT07646223
- **Lead sponsor:** Tampere University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-10-01
- **Primary completion:** 2032-12-31
- **Final completion:** 2035-12-31
- **Target enrollment:** 140 (ESTIMATED)
- **Last updated:** 2026-09-10

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07646223

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07646223, "Vancomycin Efficacy in Response to Dysbiosis in Atypical Colitis". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07646223. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*